ITM Signs an Exclusive License Agreement with Grand Pharma to Develop & Commercialize Oncological Radiopharmaceutical Therapies in the Greater China
Shots:
- ITM to receive $635.96M up front, regulatory & commercial milestone along with royalties. GP will lead the clinical development, regulatory activities & commercialization of the products in the licensed territories
- GP gets an exclusive license for ITM-11 (n.c.a. 177Lu-edotreotide), ITM-41 (n.c.a. 177Lu-zoledronate) & diagnostic TOCscan (68Ga-edotreotide) in the licensed territory & will be responsible to supply pharmaceutical materials for clinical & commercial activities
- ITM-11 is currently being evaluated in P-III (COMPETE & COMPOSE) trials for grade 1 & 2 GEP-NETs and grade 2 & 3 GEP-NETs. ITM-41 is in preclinical development for osteosarcoma and bone metastases & TOCscan for NETs
Ref: Businesswire | Image: ITM
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
